Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

aglatimagene besadenovec - Phase 2 | CADL Pipeline | CatalystAlert

aglatimagene besadenovec

Phase 2

Candel Therapeutics, Inc. (CADL)

15%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Dec 2025~

CADLPhase 2Phase 2

Aglatimagene besadenovec Phase 2 Results Expected

aglatimagene besadenovec • Prostate Cancer

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

Last updated: 12/4/2025

Developer

CADL

Candel Therapeutics, Inc.

Biotechnology•North America•NASDAQ